PDCD1 and metastatic melanoma: A phase 1/2 clinical trial combined PD1 Ab (pembrolizumab) and ATRA for the treatment of metastatic melanoma [151] and confirmed anti-tumor activity, as evidenced by the reduction in circulating MDSCs and prolonged progression-free survival.